Clinical benefit within patient subgroups receiving c7E3 Fab (abciximab) during percutaneous coronary revascularization: Subgroup analysis from the EPIC trial

Journal of Invasive Cardiology

Volumn 8, Issue SUPPL. B, 1996, Pages

  Aguirre, Frank V ^a   Topol, Eric J ^c   Anderson, Keaven M ^b   Kleiman, Neal S ^e   Weisman, Harlan F ^b   FitzPatrick, Susan E ^e   Califf, Robert M ^d  

^a SAINT LOUIS UNIVERSITY   (United States)

^b CENTOCOR INC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e St Louis University Health Sciences Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008970165     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Owen J, Hunter-Laszlo M, Williams JK, Adams M. Thrombin activity induced by balloon angioplasty of the coronary artery in Macaca fascicularis (cynomolgus monkey). Blood Coag Fibrinol 1990;1:505-507.
2. Tschoepe D, Schultheiss HP, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993;88:37-42.
3. Bates ER, McGillem MJ, Mickelson JK, et al. A monoclonal antibody against the platelet glycoprotein IIb / IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 1991;84:2463-2469.
4. Coller BS, Folts JD, Smith SR, et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockage of GPIIb / IIIa receptors. Circulation 1989;80:1766-1774.
5. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
6. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881-886.
7. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486-502.
8. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med 1991;115:256-265.
9. Mock MB, Holmes DR Jr, Vlietstra RE, et al. Percutaneous transluminal coronary angioplasty (PTCA) in the elderly patient: Experience in the National Heart, Lung, and Blood Institute PTCA Registry. Am J Cardiol 1984;53:89C-91C.
10. Philippides G, Jacobs AK, Kelsey SF, et al. Changing profiles and late outcome of women undergoing PTCA: A report from the NHLBI PTCA Registry (Abstr). J Am Coll Cardiol 1992;19(suppl A):138A.
11. Bredlau CE, Roubin GS, Leimgruber PP, et al. In-hospital morbidity and mortality in patients undergoing elective coronary angioplasty. Circulation 1984;72:1044-1052.
12. Ellis SG, Roubin GS, King SB III, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372-379.
13. Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary angioplasty: Current experience and analysis. J Am Coll Cardiol 1992;19:1641-1652.
14. Warrell RP, Hultin MB, Coller BS. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med 1979;66:226-228.
15. Lefkovits J, Anderson K, Weisman H, Topol E, for the EPIC Investigators. Increased Risk of Non-Q MI Following DCA: Evidence for a Platelet Dependent Mechanism from the EPIC trial (Abstr). Circulation 1994;90:127.
16. Lefkovits J, Stone G, Anderson K, Weisman H, Topol E, for the EPIC Investigators. Can conjunctive platelet glycoprotein IIb/IIIa receptor blockade improve outcomes of coronary interventions for restenotic lesions? (Abstr) Circulation 1995;(Suppl):101.
17. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
18. Lincoff AM, Tcheng JH, Bass TA, et al. A multicenter, randomized, double-blind pilot trial of standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody 7E3 during percutaneous coronary revascularization (Abstr). J Am Coll Cardiol 1995;25:80A.